RT Journal Article
SR Electronic
T1 Seroprevalence and molecular characterization of viral hepatitis and HIV co-infection in the Central African Republic
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.08.24.23294539
DO 10.1101/2023.08.24.23294539
A1 Basimane-Bisimwa, Parvine
A1 Koyaweda, Giscard Wilfried
A1 Ngaïganam, Edgarthe
A1 Vickos, Ulrich
A1 Sibiro, Ornella Anne Demi
A1 Yambiyo, Brice Martial
A1 Sombié, Benjamin Seydou
A1 Pélembi, Pulchérie
A1 Moussa, Sandrine
A1 Bekondi, Claudine
A1 Giles-Vernick, Tamara
A1 Manirakiza, Alexandre
A1 Vray, Muriel
A1 Komas, Narcisse Patrice Joseph
YR 2023
UL http://medrxiv.org/content/early/2023/08/24/2023.08.24.23294539.abstract
AB Background The Central African Republic (CAR) is one of the countries with the highest prevalence of viral hepatitis infection in the world. The present study describes the geographic distribution of viral hepatitis infections and molecular characterization of these viruses in the CAR.Methodology Out of 12,599 persons enrolled during the 4th Multiple Indicator Cluster Survey of 2010 in the CAR, 10,621 Dried Blood Spot (DBS) samples were obtained and stored at -20°C. Of these DBS, 4,317 samples were randomly selected to represent all regions of the CAR. Serological tests for hepatitis B, D, and C viruses were performed using the ELISA technique. Molecular characterization was performed to identify strains.Results Of the 4,317 samples included, 53.2% were males and 46.8% females. The HBsAg prevalence among participants was 12.9% and that HBc-Ab was 19.7%. The overall prevalence of the HCV was 0.6%. Co-infection of HIV/HBV was 1.41% and that of HBV/HDV was 16.6%. A total of 77 HBV, 6 HIV, and 6 HDV isolates were successfully sequenced, with 72 HBV (93.5%) strains belonging to genotype E and 5 (6.5%) isolates belonging to genotype D. The 6 HDV isolates all belonged to clade 1, while 4 recombinants sub-type were identified among the 6 isolates of HIV.Conclusion Our study found a high prevalence of HBV, HBV/HDV and HBV/HIV co-infection, but a low prevalence of HCV. CAR is still in an area of high HBV endemicity. This study’s data and analyses would be useful for establishing an integrated viral hepatitis and HIV surveillance program in the CAR.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Comite Scientifique charge de Validation des Protocoles et Resultats de Recherche en Sante -Scientific Committee in charge of validating health research protocols and results - of Faculty of Health Sciences of University of Bangui gave ethical approval for this work under 6/UB/FACSS/CSVPRS/12I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript